清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer

医学 乳腺癌 肿瘤科 癌症 梅德林 内科学 政治学 法学
作者
Li Sun,Adam R. Brentnall,Shreeya Patel,Diana S. M. Buist,Erin J. Aiello Bowles,D. Gareth Evans,Diana Eccles,John L. Hopper,Shuai Li,Melissa C. Southey,Stephen W. Duffy,Jack Cuzick,Isabel dos‐Santos‐Silva,Alec Miners,Zia Sadique,Li Yang,Rosa Legood,Ranjit Manchanda
出处
期刊:JAMA Oncology [American Medical Association]
卷期号:5 (12): 1718-1718 被引量:125
标识
DOI:10.1001/jamaoncol.2019.3323
摘要

Moving to multigene testing for all women with breast cancer (BC) could identify many more mutation carriers who can benefit from precision prevention. However, the cost-effectiveness of this approach remains unaddressed.To estimate incremental lifetime effects, costs, and cost-effectiveness of multigene testing of all patients with BC compared with the current practice of genetic testing (BRCA) based on family history (FH) or clinical criteria.This cost-effectiveness microsimulation modeling study compared lifetime costs and effects of high-risk BRCA1/BRCA2/PALB2 (multigene) testing of all unselected patients with BC (strategy A) with BRCA1/BRCA2 testing based on FH or clinical criteria (strategy B) in United Kingdom (UK) and US populations. Data were obtained from 11 836 patients in population-based BC cohorts (regardless of FH) recruited to 4 large research studies. Data were collected and analyzed from January 1, 2018, through June 8, 2019. The time horizon is lifetime. Payer and societal perspectives are presented. Probabilistic and 1-way sensitivity analyses evaluate model uncertainty.In strategy A, all women with BC underwent BRCA1/BRCA2/PALB2 testing. In strategy B, only women with BC fulfilling FH or clinical criteria underwent BRCA testing. Affected BRCA/PALB2 carriers could undertake contralateral preventive mastectomy; BRCA carriers could choose risk-reducing salpingo-oophorectomy (RRSO). Relatives of mutation carriers underwent cascade testing. Unaffected relative carriers could undergo magnetic resonance imaging or mammography screening, chemoprevention, or risk-reducing mastectomy for BC risk and RRSO for ovarian cancer (OC) risk.Incremental cost-effectiveness ratio (ICER) was calculated as incremental cost per quality-adjusted life-year (QALY) gained and compared with standard £30 000/QALY and $100 000/QALY UK and US thresholds, respectively. Incidence of OC, BC, excess deaths due to heart disease, and the overall population effects were estimated.BRCA1/BRCA2/PALB2 multigene testing for all patients detected with BC annually would cost £10 464/QALY (payer perspective) or £7216/QALY (societal perspective) in the United Kingdom or $65 661/QALY (payer perspective) or $61 618/QALY (societal perspective) in the United States compared with current BRCA testing based on clinical criteria or FH. This is well below UK and US cost-effectiveness thresholds. In probabilistic sensitivity analysis, unselected multigene testing remained cost-effective for 98% to 99% of UK and 64% to 68% of US health system simulations. One year's unselected multigene testing could prevent 2101 cases of BC and OC and 633 deaths in the United Kingdom and 9733 cases of BC and OC and 2406 deaths in the United States. Correspondingly, 8 excess deaths due to heart disease occurred in the United Kingdom and 35 in the United States annually.This study found unselected, high-risk multigene testing for all patients with BC to be extremely cost-effective compared with testing based on FH or clinical criteria for UK and US health systems. These findings support changing current policy to expand genetic testing to all women with BC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
多情的中蓝完成签到,获得积分10
刚刚
小红帽完成签到 ,获得积分20
25秒前
外向的涵雁完成签到,获得积分10
30秒前
受伤问凝完成签到 ,获得积分10
33秒前
霸气的慕山完成签到,获得积分10
50秒前
幸福海之完成签到,获得积分10
53秒前
syvshc的应助被科研通管家采纳,获得10
56秒前
栀盎完成签到 ,获得积分10
57秒前
慧子完成签到 ,获得积分10
1分钟前
稳重的从寒完成签到,获得积分10
1分钟前
Haibrar完成签到 ,获得积分10
1分钟前
云峤完成签到 ,获得积分10
1分钟前
xBiomeOS发布了新的文献求助30
1分钟前
含蓄的雪冥完成签到,获得积分10
1分钟前
大方的仙人掌完成签到,获得积分10
2分钟前
蝎子莱莱xth完成签到,获得积分0
2分钟前
yoqalux完成签到 ,获得积分10
2分钟前
氢锂钠钾铷铯钫完成签到,获得积分10
2分钟前
Square完成签到,获得积分10
2分钟前
糟糕的翅膀完成签到,获得积分0
2分钟前
搜集达人的应助被12彡采纳,获得10
2分钟前
白奕发布了新的文献求助10
2分钟前
xiaotan000完成签到,获得积分10
2分钟前
2分钟前
12彡发布了新的文献求助10
2分钟前
2分钟前
科研通AI6.3的应助被白奕采纳,获得10
2分钟前
xBiomeOS发布了新的文献求助30
2分钟前
2分钟前
蓝梦诗音完成签到 ,获得积分10
2分钟前
ValerieLI发布了新的文献求助10
2分钟前
2分钟前
syvshc的应助被科研通管家采纳,获得10
2分钟前
从容的嫣娆完成签到,获得积分10
2分钟前
靓丽花瓣完成签到,获得积分10
3分钟前
无极微光的应助被Lanyiyang采纳,获得20
3分钟前
霸气的高丽完成签到,获得积分10
3分钟前
3分钟前
3分钟前
柠檬水完成签到 ,获得积分10
3分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185453
求助须知:如何正确求助?哪些是违规求助? 9574168
关于积分的说明 21834496
捐赠科研通 7783067
什么是DOI,文献DOI怎么找? 3434570
关于科研通互助平台的介绍 2558912
邀请新用户注册赠送积分活动 2481326